Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1
From December 2022 to January 2023, SARS-CoV-2 infections caused by BA.5 and BF.7 subvariants of B.1.1.529 (Omicron) spread in China. It is urgently needed to evaluate the protective immune responses in the infected individuals against the current circulating variants to predict the future potential...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2023.2225638 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850112164829855744 |
|---|---|
| author | Shuo Liu Ziteng Liang Jianhui Nie Wei bo Gao Xinyi Li Li Zhang Yuanling Yu Youchun Wang Weijin Huang |
| author_facet | Shuo Liu Ziteng Liang Jianhui Nie Wei bo Gao Xinyi Li Li Zhang Yuanling Yu Youchun Wang Weijin Huang |
| author_sort | Shuo Liu |
| collection | DOAJ |
| description | From December 2022 to January 2023, SARS-CoV-2 infections caused by BA.5 and BF.7 subvariants of B.1.1.529 (Omicron) spread in China. It is urgently needed to evaluate the protective immune responses in the infected individuals against the current circulating variants to predict the future potential infection waves, such as the BQ.1.1, XBB.1.5, and CH1.1 variants. In this study, we constructed a panel of pseudotyped viruses for SARS-CoV-2 for the past and current circulating variants, including D614G, Delta, BA.1, BA.5, BF.7, BQ.1.1, XBB.1.5 and CH.1.1. We investigated the neutralization sensitivity of these pseudotyped viruses to sera from individuals who had BA.5 or BF.7 breakthrough infections in the infection wave of last December in China. The mean neutralization ID50 against infected variants BA.5 and BF.7 are 533 and 444, respectively. The highest neutralizing antibody level was observed when tested against the D614G strain, with the ID50 of 742, which is about 1.52-folds higher than that against the BA.5/BF.7 variant. The ID50 for BA.1, Delta, and BQ.1.1 pseudotyped viruses were about 2–3 folds lower when compared to BA.5/BF.7. The neutralization activities of these serum samples against XBB.1.5 and CH.1.1 decreased 7.39-folds and 15.25-folds when compared to that against BA.5/BF.7. The immune escape capacity of these two variants might predict new infection waves in future when the neutralizing antibody levels decrease furtherly. |
| format | Article |
| id | doaj-art-399c70797b084abca6f53d659c6e15db |
| institution | OA Journals |
| issn | 2222-1751 |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-399c70797b084abca6f53d659c6e15db2025-08-20T02:37:28ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512023-12-0112210.1080/22221751.2023.2225638Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1Shuo Liu0Ziteng Liang1Jianhui Nie2Wei bo Gao3Xinyi Li4Li Zhang5Yuanling Yu6Youchun Wang7Weijin Huang8Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s Republic of ChinaChinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s Republic of ChinaDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People’s Republic of ChinaDepartment of Emergency, Peking University People’s Hospital, Beijing, People’s Republic of ChinaWest China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, People’s Republic of ChinaDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People’s Republic of ChinaChangping Laboratory, Beijing, People’s Republic of ChinaChinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s Republic of ChinaDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People’s Republic of ChinaFrom December 2022 to January 2023, SARS-CoV-2 infections caused by BA.5 and BF.7 subvariants of B.1.1.529 (Omicron) spread in China. It is urgently needed to evaluate the protective immune responses in the infected individuals against the current circulating variants to predict the future potential infection waves, such as the BQ.1.1, XBB.1.5, and CH1.1 variants. In this study, we constructed a panel of pseudotyped viruses for SARS-CoV-2 for the past and current circulating variants, including D614G, Delta, BA.1, BA.5, BF.7, BQ.1.1, XBB.1.5 and CH.1.1. We investigated the neutralization sensitivity of these pseudotyped viruses to sera from individuals who had BA.5 or BF.7 breakthrough infections in the infection wave of last December in China. The mean neutralization ID50 against infected variants BA.5 and BF.7 are 533 and 444, respectively. The highest neutralizing antibody level was observed when tested against the D614G strain, with the ID50 of 742, which is about 1.52-folds higher than that against the BA.5/BF.7 variant. The ID50 for BA.1, Delta, and BQ.1.1 pseudotyped viruses were about 2–3 folds lower when compared to BA.5/BF.7. The neutralization activities of these serum samples against XBB.1.5 and CH.1.1 decreased 7.39-folds and 15.25-folds when compared to that against BA.5/BF.7. The immune escape capacity of these two variants might predict new infection waves in future when the neutralizing antibody levels decrease furtherly.https://www.tandfonline.com/doi/10.1080/22221751.2023.2225638SARS-CoV-2neutralizing antibodybreakthrough infectionconvalescence serumBA.5/BF.7 |
| spellingShingle | Shuo Liu Ziteng Liang Jianhui Nie Wei bo Gao Xinyi Li Li Zhang Yuanling Yu Youchun Wang Weijin Huang Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1 Emerging Microbes and Infections SARS-CoV-2 neutralizing antibody breakthrough infection convalescence serum BA.5/BF.7 |
| title | Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1 |
| title_full | Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1 |
| title_fullStr | Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1 |
| title_full_unstemmed | Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1 |
| title_short | Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1 |
| title_sort | sera from breakthrough infections with sars cov 2 ba 5 or bf 7 showed lower neutralization activity against xbb 1 5 and ch 1 1 |
| topic | SARS-CoV-2 neutralizing antibody breakthrough infection convalescence serum BA.5/BF.7 |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2023.2225638 |
| work_keys_str_mv | AT shuoliu serafrombreakthroughinfectionswithsarscov2ba5orbf7showedlowerneutralizationactivityagainstxbb15andch11 AT zitengliang serafrombreakthroughinfectionswithsarscov2ba5orbf7showedlowerneutralizationactivityagainstxbb15andch11 AT jianhuinie serafrombreakthroughinfectionswithsarscov2ba5orbf7showedlowerneutralizationactivityagainstxbb15andch11 AT weibogao serafrombreakthroughinfectionswithsarscov2ba5orbf7showedlowerneutralizationactivityagainstxbb15andch11 AT xinyili serafrombreakthroughinfectionswithsarscov2ba5orbf7showedlowerneutralizationactivityagainstxbb15andch11 AT lizhang serafrombreakthroughinfectionswithsarscov2ba5orbf7showedlowerneutralizationactivityagainstxbb15andch11 AT yuanlingyu serafrombreakthroughinfectionswithsarscov2ba5orbf7showedlowerneutralizationactivityagainstxbb15andch11 AT youchunwang serafrombreakthroughinfectionswithsarscov2ba5orbf7showedlowerneutralizationactivityagainstxbb15andch11 AT weijinhuang serafrombreakthroughinfectionswithsarscov2ba5orbf7showedlowerneutralizationactivityagainstxbb15andch11 |